Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| MongoDB | Palo Alto Networks | Eli Lilly and Company | |
|---|---|---|---|
| Moat rating | narrow The FY2026 10-K frames a 'rapidly evolving and highly competitive' database market where the principal rivals — 'legacy database providers and large cloud providers' — hold explicit advantages: 'longer operating histories, more established relationships … significantly greater financial, technical, marketing or other resources … broader global distribution,' and can offer competing products 'at a low cost or no cost.' A developer-mindshare and switching-cost position is defensible but not wide against that field. | narrow Real but bounded. The FY2025 10-K's own Competition section calls the enterprise security industry "intensely competitive" and names four categories of rival — platform incumbents (Cisco, Microsoft, Alphabet), independent security vendors (Check Point, Fortinet, CrowdStrike, Zscaler, Wiz), point-product startups, and the public cloud vendors — while conceding that "some of our competitors may have substantially greater financial, technical, and other resources, greater name recognition, larger sales and marketing budgets, broader distribution, more diversified product lines, and larger and more mature intellectual property portfolios." That record supports a defensible position, not an unassailable one: narrow, not wide. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| Moat type | switching costs A database is the system an application is built on: the 10-K states 'a database directly impacts an application's performance, scalability, flexibility and reliability,' and Atlas is 'our managed multi-cloud database-as-a-service' running the customer's live workloads — re-platforming a database is a rewrite, not a swap. | switching costs The 10-K describes an installed estate standardised on one operating system — "All of our hardware and software firewalls incorporate the PAN-OS operating system and include the same rich set of features, ensuring consistent operation across our entire product line" — across hardware, containerised CN-Series and virtual VM-Series form factors, centrally administered through Panorama and Strata Cloud Manager. That estate is monetised as recurring contract: subscription and support was 80.5% of total revenue in fiscal 2025 (80.0% in fiscal 2024, 77.1% in fiscal 2023), on terms "typically one to five years." The company's own risk factors describe the friction from the other side — customers "may face real or perceived switching costs when switching to our solutions from legacy security vendors" and "have often invested substantial personnel and financial resources to design and operate their networks... [and] may prefer to purchase from their existing suppliers rather than add or switch to a new supplier." As the incumbent in most of those estates, that friction now runs in Palo Alto's favour. | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| Leadership | co leader The 10-K positions MongoDB as the leading document database by developer mindshare but names 'legacy database providers and large cloud providers' as better-resourced rivals across the broader database market — a category leader within a market it does not lead overall. | co leader The 10-K claims parity-plus, not primacy: "We believe we generally compete favorably with our competitors on the basis of these factors as a result of the features and performance of our portfolio, the ease of integration of our security solutions with technological infrastructures, and the relatively low total cost of ownership of our products," and reports that its "products and services have been recognized as leading in 25 categories by third-party industry analysts firms." It qualifies that immediately by conceding that some competitors carry greater resources, name recognition and distribution. Independent analyst placements match a co-leader read rather than a sole-leader one — a Leader in the inaugural 2025 Gartner Magic Quadrant for Hybrid Mesh Firewalls, a Leader for the third consecutive time in the 2025 Magic Quadrant for SASE Platforms, and a Leader in the 2026 Magic Quadrant for Endpoint Protection Platforms for the fourth consecutive year — in categories that name other Leaders too. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| Pricing power | moderate Owning the IP and the roadmap ('the determination of which features are included in our free or paid offerings') gives real list-price control, but the same filing flags competitors offering database products 'at a low cost or no cost basis,' which caps it. | moderate Moderate, with the evidence pointing both ways in the same filing. Gross margin computed from the three years of income statements inside this FY2025 10-K runs 72.3% (fiscal 2023), 74.3% (fiscal 2024) and 73.4% in fiscal 2025 on revenue of $9.22 billion — against 68.8% in fiscal 2022 as reported in the prior-year 10-K (accession 0001327567-24-000029, filed September 6, 2024). Over the same span subscription and support rose from 77.1% to 80.5% of revenue: a mix shift toward software that has been margin-accretive, not margin-destructive, which is the direct answer to whether platformisation is simply discounting. Against that, the 10-K's risk factors state plainly that sales prices "may decline for a variety of reasons, including competitive pricing pressures, discounts, a change in our mix... or promotional programs," that the company "anticipate[s] that the sales prices and gross profits for our products could decrease over product life cycles," and that it "has also experienced demands for customer financing and deferred payments." Pricing is defended by bundle economics rather than commanded outright. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| Summary | MongoDB monetizes developer mindshare that began as open source: the 10-K notes 'we own the intellectual property of our offerings since we are the creators of the software,' which lets it run a 'proprietary software subscription business model' and control the roadmap. The durable asset is the document-model install base and Atlas's managed multi-cloud workloads, positioned for AI as 'the underlying database … capable of processing queries against rich and complex data structures.' The counterweight, in the filing's own words, is that the large cloud providers it depends on for Atlas hosting are also its best-resourced competitors. | A deployed firewall estate is the anchor. Every Palo Alto firewall — appliance, VM-Series, CN-Series, Cloud NGFW — runs the same PAN-OS with the same feature set and is managed from one console, so the security policy, the operator skills and the integration work are all specific to the vendor, and 80.5% of fiscal 2025 revenue is the recurring subscription and support contract sitting on top of it (10-K, Business and Risk Factors). Platformisation is the attempt to convert that anchor into wallet share: the 10-K states the strategy as helping customers "simplify their security architectures through consolidating disparate point products" by packaging offerings "into a tightly integrated architecture," and the acquisitions are consistent with it — IBM's QRadar assets in August 2024 "to help accelerate the growth of our Cortex business," Protect AI in July 2025, and the CyberArk agreement signed in July 2025. The evidence that consolidation is real rather than a discount: remaining performance obligation grew 36% year over year to $18.4 billion against 31% revenue growth in the quarter ended April 30, 2026 (Palo Alto Networks FQ3 2026 results release, June 2, 2026) — contracted future obligation compounding faster than recognised revenue, which is the opposite of what buying revenue with price would produce. The counterweight is disclosed in the same filings: the 10-K warns sales prices "may decline for a variety of reasons, including competitive pricing pressures, discounts," anticipates that "sales prices and gross profits for our products could decrease over product life cycles," and reports "demands for customer financing and deferred payments." Against CrowdStrike in security operations and Zscaler in SASE, Palo Alto is competing across the whole surface rather than defending a monopoly on any one of them — hence a narrow moat, not a wide one. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| Chain position | Layer-10 application-layer data platform — the operational database under AI and general software workloads. | A security-software consumer of the AI stack rather than a supplier to it — it buys compute to run Precision AI and now sells protection for the stack itself through Prisma AIRS (AI model scanning, posture management, red teaming, runtime and AI-agent security). Distribution is two-tier and concentrated: 44.2% of fiscal 2025 revenue came through three distributors and more than 8,500 channel partners, while no single end-customer exceeded 10% of revenue in fiscal 2025, 2024 or 2023. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. |